Assessing Physical Function in Sickle Cell Patients Taking Voxelotor - Trial NCT06023199
Access comprehensive clinical trial information for NCT06023199 through Pure Global AI's free database. This phase not specified trial is sponsored by Inova Health Care Services and is currently Recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Inova Health Care Services
Timeline & Enrollment
N/A
Oct 23, 2023
Jun 15, 2024
Primary Outcome
Participant's Physical Performance Using 6 Minutes Walk Test (6MWT) Pre and Post Treatment with Voxelotor.
Summary
Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to
 reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining
 the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few
 published reports on the effects of treatment on physical function in patients with SCD. The
 hypothesis to be tested is that anemic SCD patients will have improvements in performance
 after 6 months of voxelotor treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06023199
Non-Device Trial